Divalproex Sodium Tablet, Delayed Release
Product Images NDC 0904-6860

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 0904-6860). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Major Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

F0a664b1 B47c 49e8 Bba4 754bb4e2c182 00

Divalproex Sodium delayed-release tablets label from Major Pharmaceuticals, showing 500 mg strength. The label indicates unit dose packaging with 90 tablets, instructions for pharmacist to dispense with medication guide, and storage conditions. The label includes the NDC 0904-6861-90 and directions for use, manufacturer and distributor information, and a barcode at the bottom.*

FDA Label Image

Carton Label (Image 01)

Label for Divalproex Sodium delayed-release tablets, USP, 250 mg strength, oral tablet dosage form by Major Pharmaceuticals. The label indicates unit dose packaging with 100 tablets, emphasizing dispensing with a medication guide and restricted to prescription use only. Additional usage, storage, and manufacturing details are also included.*

FDA Label Image

Spl-divalproex-figure-1 (Spl Divalproex Figure 1)

A bar chart titled "Figure 1" showing percentage comparisons in two studies: Study 1 (YMRS) and Study 2 (MRS). Each study compares placebo (PBO) and Divalproex Sodium (DVPX) with DVPX bars showing higher percentages (60% and 58%) than placebo (26% and 29%). Percentage values are labeled above each bar.*

FDA Label Image

Spl-divalproex-figure-2 (Spl Divalproex Figure 2)

A cumulative distribution plot showing the percentage reduction in CPS rate among patients treated with Divalproex Sodium (DVPX) compared to placebo. The graph depicts improvement, no change, or worsening of symptoms against the percentage of patients, illustrating the drug's effect versus placebo.*

FDA Label Image

Spl-divalproex-figure-3 (Spl Divalproex Figure 3)

A chart titled 'Figure 3' showing percent reduction in CPS rate on the vertical axis versus percent of patients on the horizontal axis. It compares improvement or worsening in CPS rate between high dose and low dose groups of Divalproex Sodium, with lines representing each dose group.*

FDA Label Image

Spl-divalproex-figure-4 (Spl Divalproex Figure 4)

A bar graph titled 'Figure 4 Mean 4-week Migraine Rates' showing comparative migraine rates for Placebo and Divalproex Sodium (DVPX) across two studies. The y-axis measures migraine rates from 0 to 6, with Placebo bars higher than DVPX bars in both Study 1 and Study 2, indicating lower migraine rates with Divalproex Sodium treatment in the studies.*

FDA Label Image

Spl-divalproex-structure (Spl Divalproex Structure)

Chemical structure diagram of divalproex sodium showing its molecular arrangement with sodium ion and organic groups. The image illustrates the repeating unit of divalproex sodium polymer.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.